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Poster Session II 113who had HCT since 2001 with the use of 5 myeloablative condi-
tioning regimens: BuCY 6 Thymoglobulin, FluBu, or FluBu 1
Thymoglobulin with different doses of Flu designated Flu[1(120
mg/m2)]BuThy and Flu[2(250 mg/m2)]BuThy. Grafts consisted
of unmanipulated bone marrow or growth factor-mobilized blood
cells from related or unrelated donors, except for 9 patients who re-
ceived BuCY and mobilized blood cells from related donors that
were 90% depleted of T-cells. Donor chimerism in recipient blood
T-cells (CD3) and granulocytes (CD331) was measured at day 80
after HCT.
Patient characteristics in the 5 groups were similar: median age
49, 91% MDS or AML (64% high-risk), 51% unrelated donors,
88% PBSC, 59% HCT-CI $1. Donor chimerism of granulocytes
was complete by day 180 in all groups, but persistent mixed
T-cell chimerism was observed in certain groups. Compared to pa-
tients who received BuCY with unmanipulated allografts, the inci-
dence of mixed chimerism with .50% recipient T-cells was
higher among patients who received Flu, bone marrow grafts or
T-cell depleted grafts (e.g., Flu[1]BuThy: OR 14.5, p\ 0.0001).
Most patients with mixed chimerism at day 80 had full donor
T-cell chimerism at 1 yr after HCT, but some patients with
malignancy in complete remission at 3 yr continue to have per-
sistent mixed T-cell chimerism.
Compared to BuCY controls, improved outcomes with reduced
regimen-related toxicity were observed in the 22 patients who re-
ceived Flu[1]BuThy. After adjustment for age, disease risk, donor
type,HCT-CI and prior CMV infection in the recipient, the Flu[1]-
BuThy group had significantly lower rates of acute GvHD (HR
0.50, p 5 0.02), chronic GvHD (HR 0.31, p 5 0.003) and NRM
(HR 0.25, p 5 0.05), although relapse was not significantly in-
creased (HR 1.13, p 5 0.87) and overall survival was not signifi-
cantly improved (HR 5 0.60, p 5 0.19). In contrast, NRM and
survival in the Flu[2]BuThy and BuCY groups showed no statisti-
cally significant differences. In general, addition of thymoglobulin
for GvHD prophylaxis significantly reduced the incidence of
chronic GvHD. A prospective, randomized trial is needed to deter-
mine whether superior outcomes can be achieved after conditioning
with Flu[1]BuThy as compared with BuCy.305
THYMOGLOBULIN RABBIT ANTI-THYMOCYTE GLOBULINS (r-ATG)
INDUCES FASTER PLATELET RECOVERY AND DOES NOT SUPPRESS
GRANULOCYTE ENGRAFTMENT IN A NON-MYELOABLATIVE STEM
CELL TRANSPLANTATION SETTING
Shapira, M.Y., Resnick, I.B., Gesundeheidt, B., Bitan, M.,
Ackerstein, A., Samuel, S., Drey, L., Verkholevsky, Y., Slavin, S.,
Or, R. Hadassah – Hebrew University Medical Center, Jerusalem, Israel.
Introduction: : The role of anti thymocyte globulin in GVHD
prevention is well established, but it is also known that anti thymo-
cyte globulin induces leucopenia and thrombocytopenia and as such
might theoretically delay engraftment. Additionally, fast platelet
engraftment is a marker for good hematopoietic stem cell graft
function.We have prospectively compared the effect of Thymoglo-
bulin on engraftment of granulocytes and platelets following a single
non-myeloablative conditioning protocol in a randomized study.
Methods: 28 consecutive patients undergoing SCT were condi-
tioned with the NST protocol (I.V. fludarabine 30 mg/m2/day
(days -10 to -5) and I.V. busulfex (3.2 mg/kg on days 6 and 5),
with or without I.V. Thymoglobulin according to randomization
(days 4 to 1). Thymoglobulin dosing schedule: a cumulative dose
of 7.5 mg/kg r-ATG was given with the following program 0.5
mg/kg day -4, 2.0 mg/kg day -3, 2.5 mg/kg day -2, 2.5 mg/kg day
-1. Patients were followed for engraftment of leukocytes and plate-
lets. Results: only one patient rejected the graft (conditioned with-
out Thymoglobulin, NS). In 4 patients underlying disease
progression prevented engraftment of either ANC or platelets (2
per group). The median time to ANC engraftment was similar be-
tween the groups, 156 2.8 and 146 2.9 days for the Thymoglobu-
lin and control groups respectively (p5 0.21). However, themedian
time for platelet engraftment was significantly shorter in patients re-
ceiving Thymoglobulin as part of the conditioning. Platelet recov-
ery occurred 9.5 6 1.2 and 11 6 2.5 days for the Thymoglobulinand control groups respectively (p 5 0.018). Conclusions: In the
non-myeloablative setting, Thymoglobulin induces faster platelet
recovery and does not delay ANC engraftment.306
A COMPARISON OF MEASURED VS. CALCULATED CREATININE CLEAR-
ANCE AND THEIR LACK OF ASSOCIATION WITH RENAL REGIMEN RE-
LATED TOXICITY AFTER AUTOLOGOUS AND ALLOGENEIC BMT
Hahn, T., Dunford, L., Butler, B., Stento, N., Smiley, S., Battiwalla,M.,
McCarthy, P.L. Roswell Park Cancer Institute, Buffalo, NY.
Standard BMT eligibility criteria generally include glomerular
filtration rate (GFR) $50 ml/min for myeloablative and GFR
$40 ml/min for nonmyeloablative regimens. The most accurate,
but costly, method ofGFRmeasurement is urinary clearance ofmo-
lecular isotopes such as 99m Tc-DTPA. In BMT pts, GFR is com-
monly estimated by creatinine clearance in a 24 hour urine
collection (24 hr CrCl), a time-consuming and error-pronemethod.
4 equations incorporate different clinical variables to estimate CrCl:
Cockroft-Gault (CG), modified CG (mCG), Modification of Diet
in Renal Disease 1 (MDRD1) and MDRD2. The study objectives
were to determine which of 4 calculations consistently underesti-
mates measured CrCl pre-BMT and to determine if any were
correlated with renal regimen related toxicity (RRT). We retro-
spectively analyzed 100 consecutive allo (n 5 50) or auto (n 5 50)
BMT pts from 1/06 to 4/07 to compare measured CrCl with each
of the 4 formulas using linear regression and Wilcoxon signed
rank test. Renal RRT was defined using the Bearman scale: no in-
crease from baseline serum Cr (gr 0), any increase over baseline
(gr 1), doubling of baseline (gr 2), dialysis (gr 3), or death from renal
RRT (gr 4), with an incidence of 24%, 57%, 18%, 1% and 0%, re-
spectively. All 4 formulas were significantly (p\ .001) correlated to
measured CrCl with correlation coefficients (R) 5 .63 (CG), .61
(mCG), .50 (MDRD1) and .54 (MDRD2). When stratified by
gender, CG had the highest R for women (R 5 .679, p\ .001),
while MDRD1 had the highest for men (R 5 .40, p 5 .003).
MDRD1 consistently underestimated CrCl in the highest propor-
tion of pts (65%, p \ .001), compared to MDRD2 (65%, p 5
.001), mCG (54%, p5NS) and CG (33%, p 5 .001). Measured
CrCl, serum Cr, and all 4 calculations were not predictive of renal
RRT post-BMT. Significant univariate predictors of gr 2–3 renal
RRT were: alloBMT, reduced intensity/nonmyeloablative regi-
mens (RICNMA), KPS#80 and albumin#3.7 g/dL. In alloBMT,
BMI .35, KPS #80 and albumin #3.8 g/dL were significantly as-
sociated with gr 2–3 renal RRT, however in autoBMT baseline se-
rum Cr$1.1 was the only significant factor. Any of the 4 equations
can replace the 24 hr CrCl. CG is closest to, but overestimates CrCl
in 67% of pts. In comparison,MDRD1 consistently underestimates
CrCl in 65%. Larger analyses may better define subgroups at risk
for renal RRT. Our results suggest a lower CrCl threshold may
be acceptable for BMT due to the relatively low gr 2–4 renal
RRT incidence observed.307
MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION IN 424
PATIENTS USING BUSULFAN AND CYCLOPHOSPHAMIDE
Floisand, Y.1, Tjonnfjord, G.E.1, Gedde-Dahl d.y., T.1, Heldal, D.1,
Egeland, T.2, Dybedal, I.1, Holme, P.A.1, Brinch, L.C.1. 1Rikshospitalet
University Hospital, Oslo, Norway; 2Rikshospitalet University Hospital,
Oslo, Norway.
Background/Aims: From 1985 to 2007, 424 adult patients re-
ceived Busulfan Cyclophosphamide (Bu4Cy2) as conditioning regi-
men before allogeneic stem cell transplantation in our institution.
In this study we analyzed this group with regard to overall survival,
LFS, TRM and the incidence of complications.
Patient Material/Methods: 424 patients underwent ASCT;
43% female (N 5 185) and 57% male(N 5 239). Median age was
39.9 y (15.4–60.7). 263 patients (62%) received transplants from
family donors and 161 (38%) from matched unrelated donors
114 Poster Session II(MUD). Eligible donors included siblings sharing bothHLAhaplo-
types and haploidentical family donors with a maximum of one an-
tigen mismatch on A or B (serology) or DRB1 on the non-shared
haplotype, and MUD identical on A and B (serology), DRB1,
DQB1 before 2000 and allelic A, B, C, DRB1, and DQB1 10/10
or 9/10 allelic match from 2000.
ASCT was performed due to:
CML: 138 patients (33%),
AML: 169 patients (40%),
ALL: 72 patients (17%), all patients were high risk, mainly with
t(9;22) or relapsed disease, other indications: N 5 45 (10%).
GvHD prophylaxis was cyclosporine A (CyA) and iv methotrex-
ate. Acute GvHD$ grade II was treated with increased immunosu-
pression (CyA and methylprednisolone (2 mg/kg/day)) and steroid
refractory GvHD with ATG or other immunosuppressants. Re-
sults: The median age at transplantation increased significantly in
the study period (p 5 0.001).
The number of CML patients undergoing ASCT declined from
43% before 2000, to 21% after 2000 and 5.5% in 2006.
Overall Survival (OS):The 5 yOSwas 66% and 47% in patients
with family donors and MUD respectively.
CML: The 5 y OS for those with family donor or MUDwas 83%
and 52%.
AML: The 5 y OS for the patients with family donor: 63% and
MUD: 49%.
ALL: The 5 y OS for patients with family donor 45% and MUD
42%.
Complications registered in patients transplanted up to 2005:
GVHD: Acute GvHD occurred in 46.2%; aGvHD grade II-IV
31.2%. The incidence of chronic GvHD was 36%; 23% limited
and 13% extensive.
Infections: Proven or probable invasive fungal infections were
registered in 12.8%. CMV infection and disease was seen in
19.5% and 5.1% of the patients respectively.
Mortality: Mortality before day 100 was 11.4% and 25% in
the family donor and MUD groups, respectively. Overall non-re-
lapse mortality was 29%. Conclusion: Our results compare favor-
ably with previously published series, indicating that this
conditioning regimen remains a good option in the myeloablative
setting.308
FACTORS AND PREDICTORS ASSOCIATED WITH PERIPHERAL BLOOD
STEM CELL YIELD IN VOLUNTEER DONORS-TAIWAN EXPERIENCE
Chen, S.-H.1, Lu, C.-J.2, Wen, S.-H.3, Shyr, M.-H.2, Yang, K.-L.2.
1Hualien Tzu-Chi Hospital, Hualien, Taiwan; 2Buddhist Tzu-Chi
Stem Cell Center, Hualien, Taiwan; 3Tzu-Chi University, Hualien,
Taiwan.
Background: Successful allogeneic PBSC transplantation de-
pends upon the infusion of a sufficient number of CD341 cells.
Limited information is available about the factors predicting for sat-
isfactory G-CSF-induced PBSC collection from healthy donors.
Materials andMethods:G-CSF was administered subcutaneously
daily at a dose of 8.3–11 ug/kg for 5 days for mobilization. At pres-
ent pre-CD341 cell count is the most reliable predictor of PBSC
yield. The mean CD341 concentration(106/l) was enumerated
from the final PBSC product and represented the stem cell yield
in this study. We analysed the relationship between donor
characteristics including age, body weight, BMI,WBC count, abso-
lute mononuclear cell count(MNC), circulating immature cell
count (CIC:circulating myeloblasts1promyelocytes1myelocytes1
metamyelocytes1erythroblasts), hematopoietic progenitor cell
count(HPC), platelet count and immature reticulocyte fractio-
n(IRF) and the yields of CD341 cells from 300 healthy volunteer
donors. Results: Poor mobilizer(CD341 cell\ 2  106/kg recip-
ient body weight) comprised 5% of our total volunteer PBSC do-
nors. Male donors have significant greater mean CD341 cell
yields(mean 5 2433  106/l) than that of female donors(mean 5
1670 106/l) from t-test analysis. In univariate correlation analysis,
body weight, BMI, WBC count, absolute MNC, CIC and pre-
CD341 cell count before harvest were significantly positively cor-
related with the CD341 cells, but age is negatively correlated withthe CD341 cells. The correlation analysis also showed that the
body weight, BMI, WBC count, absolute MNC, CIC and HPC
were positively correlated with pre-CD341 cell count(Pearson cor-
relation coefficient is 0.403, 0.429, 0.46, 0.199, 0.46, 0.337 respec-
tively). Conclusion: In this study, we found that gender, age, body
weight, BMI, CIC and pre-CD341 cell count were themost impor-
tant factors for predicting PBSC yields.309
PRETRANSPLANTATION ASSESSMENT OF MORTALITY (PAM) RISK
SCORE CANPREDICT COST FORPATIENTS SUBMITTEDTOAUTOLOGOUS
AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kerbauy, F.R., Ribeiro, A.F., Toledo, C., Lisboa, L.F., Hamerschlak, N.
Hospital Israelita Albert Einstein, Sa˜o Paulo, Brazil.
Introduction: Death risk related to hematopoietic stem cell
transplantation (HSCT) is associated to donor and recipient factors.
According to theses factors a Pretransplant Assessment Mortality
(PAM) risk score was developed to predict mortality after HSCT
(Parimon T et al, 2006). Predicting mortality and cost before trans-
plant is useful to prevent complications and establish early treat-
ment. In addition, the cost of procedures related to HSCT is
usually high and its best understanting can help in projection of
the financial benefits of preventive strategies and help in negotiation
of higher reimbursements rates.Objectives: To validate PAM risk
score in our population and correlate different PAM risk groups
with transplantation cost. Material and Methods: One-hundred
and sixteen consecutive patients were retrospectively evaluated.
Twenty-seven were treated with autologous and 89 with alogeneic
HSCT from 2003 to 2006. PAM risk score was applied using the in-
ternet tool provided in the original publication (http://cdsmed.fhcr-
c.org/pam/). The transplantation cost was calculated for each
patient using the total amount spent until dischargement after en-
graftment. Classificatory variables were calculated usingChi-square
or Fisher test. Continuous variables were calculated usingWilcoxon
or Kruskal-Wallis test. Survival was compared by Kaplan-Meier
survival curves.Results:There was no difference in overall survival
between different risk groups for patients treated with alogeneic
HSCT (P5 0.10). There was a superior overall survival for patients
in low risk score treated with autologous HSCT (p 5 0.03). When
all patients were compared independently of HSCT type, there was
a significant difference in overall survival for patients in low, inter-
mediate and high risk score. Finally there was a significant statistical
difference in cost for patients in different risk groups where high
risk patients cost more than intermediate and low risk patients. (P
5 0.008).Conclusions: PAM risk score can be a useful tool to pre-
dict mortality and cost in HSCT. It can also predict cost related to
HSCT.310
RAPID ENGRAFTMENT AND LOW RATES OF GRAFT-VERSUS-HOST DIS-
EASE (GVHD) FOLLOWING REDUCED INTENSITY CONDITIONING (RIC)
WITH FLUDARABINE/BUSULFAN/ATG (FBA) AND STEM CELL TRANS-
PLANTATION (SCT) USING UNRELATED DONORS (URD)
Hamadani, M., Awan, F.T., Elder, P., Lin, T.S., Andritsos, L.,
Blum,W., Blum, K.A., Devine, S.M. Arthur G. James Cancer Hospital,
Ohio State University, Columbus, OH.
RIC regimens are increasingly used for allogeneic SCT in pa-
tients (pts) with relative contraindications for transplantation since
they promote effective engraftment of donor cells withminimal reg-
imen related toxicity. However, following URD-SCT, high rates of
acute (a) and chronic (c) GVHD have mitigated the overall benefits
of RIC. We pursued a strategy designed to enhance full donor chi-
merismwhile potentially reducing the risk of severe acute& chronic
GVHD using a RIC regimen containing FBA followed by URD
SCT in 30 consecutive high risk pts. Selection criteria included
age .55 yrs, prior autograft, and/or high co-morbidity index (me-
dian 2, range 0–4). There were 24 male and 6 female pts with a me-
dian age of 53 years (range 22–66 yrs). Diagnoses included AML
